Alluvi, previously BI 4744, presents a promising breakthrough in weight management care. This dual stimulator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide targets demonstrates remarkable https://eternalbookmarks.com/story21937764/alluvi-a-detailed-dive-into-the-drug-s-prospects